Maravai LifeSciences Holdings (FRA:MAR) LT-Debt-to-Total-Asset : 0.36 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Maravai LifeSciences Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Maravai LifeSciences Holdings's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.36.

Maravai LifeSciences Holdings's long-term debt to total assets ratio declined from Dec. 2023 (0.40) to Dec. 2024 (0.36). It may suggest that Maravai LifeSciences Holdings is progressively becoming less dependent on debt to grow their business.

Maravai LifeSciences Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for Maravai LifeSciences Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maravai LifeSciences Holdings LT-Debt-to-Total-Asset Chart

Maravai LifeSciences Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.46

0.30

0.25

0.40

0.36

Maravai LifeSciences Holdings Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.40	0.38	0.38	0.43	0.36

Maravai LifeSciences Holdings LT-Debt-to-Total-Asset Calculation

Maravai LifeSciences Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	346.645	/	962.873
	=	0.36

Maravai LifeSciences Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	346.645	/	962.873
	=	0.36

Maravai LifeSciences Holdings (FRA:MAR) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Maravai LifeSciences Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Maravai LifeSciences Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (FRA:MAR) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

MRVI:USA MAR:Germany

Address

10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121

Website

https://www.maravai.com

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.